Recent findings have shown the curative effect of PARPi treatment in cancer depends mainly on its capacity to trap PARP1 on chromatin; thus, platinum‐sensitive ovarian cancer patients without HR‐deficient tumors could also benefit from PARPi treatment. This evidence concerns the gene PARP1 and ovarian carcinoma.